<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33725356</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1286</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Targeting Age-Related Neurodegenerative Diseases by&#xa0;AAV-Mediated Gene Therapy.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>223</EndPage><MedlinePgn>213-223</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-55035-6_15</ELocationID><Abstract><AbstractText>Age-related neurodegenerative diseases have detrimental consequences on health of many patients and result in mortality. The current treatment options are limited and usually fail to correct the underlying pathology. AAV-based gene therapies have proved to be safe based on the data available on clinical trials for several monogenic diseases. Therefore, such therapies can pave the way to treat neurodegenerative diseases likes Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Here, the advantages of AAV-based gene therapies are discussed with emphasis on efforts of developing novel capsids with superior therapeutic efficacy. Furthermore, the results of clinical trials on AD, PD, and ALS are summarized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cagin</LastName><ForeName>Umut</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>INTEGRARE, Genethon, Inserm, Univ Evry, Universit&#xe9; Paris-Saclay, Evry, France. ucagin@genethon.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAV</Keyword><Keyword MajorTopicYN="N">CNS</Keyword><Keyword MajorTopicYN="N">Capsid</Keyword><Keyword MajorTopicYN="N">Central nervous system</Keyword><Keyword MajorTopicYN="N">Neurodegeneration gene therapy</Keyword><Keyword MajorTopicYN="N">Neurodegenerative diseases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>17</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33725356</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-55035-6_15</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kurtishi A, Rosen B, Patil KS, Alves GW, Moller SG (2019) Cellular proteostasis in neurodegeneration. Mol Neurobiol 56(5):3676&#x2013;3689</Citation><ArticleIdList><ArticleId IdType="pubmed">30182337</ArticleId><ArticleId IdType="doi">10.1007/s12035-018-1334-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlou MAS, Outeiro TF (2017) Epigenetics in Parkinson&#x2019;s disease. Adv Exp Med Biol 978:363&#x2013;390</Citation><ArticleIdList><ArticleId IdType="pubmed">28523556</ArticleId><ArticleId IdType="doi">10.1007/978-3-319-53889-1_19</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchfield JS, Li Q, Wang HY, Wang RF (2015) JMJD3 as an epigenetic regulator in development and disease. Int J Biochem Cell Biol 67:148&#x2013;157</Citation><ArticleIdList><ArticleId IdType="pubmed">26193001</ArticleId><ArticleId IdType="pmc">4564304</ArticleId><ArticleId IdType="doi">10.1016/j.biocel.2015.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Marshall L, Oh G, Jakubowski JL, Groot D, He Y et al (2019) Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer's disease pathology and cognitive symptoms. Nat Commun 10(1):2246. https://doi.org/10.1038/s41467-019-10101-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10101-7</ArticleId><ArticleId IdType="pubmed">31113950</ArticleId><ArticleId IdType="pmc">6529540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787&#x2013;795</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId><ArticleId IdType="pmc">17051205</ArticleId><ArticleId IdType="doi">10.1038/nature05292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagin U, Duncan OF, Gatt AP, Dionne MS, Sweeney ST, Bateman JM (2015) Mitochondrial retrograde signaling regulates neuronal function. Proc Natl Acad Sci U S A 112(44):E6000&#x2013;E6009</Citation><ArticleIdList><ArticleId IdType="pubmed">26489648</ArticleId><ArticleId IdType="pmc">4640732</ArticleId><ArticleId IdType="doi">10.1073/pnas.1505036112</ArticleId></ArticleIdList></Reference><Reference><Citation>Casajus Pelegay E, Puzzo F, Yilmazer A, Cagin U (2019) Targeting mitochondrial defects to increase longevity in animal models of neurodegenerative diseases. Adv Exp Med Biol 1134:89&#x2013;110</Citation><ArticleIdList><ArticleId IdType="pubmed">30919333</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-12668-1_5</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Dhawan A, Kadam A, Shinde A (2018) Autophagy and mitochondria: targets in neurodegenerative disorders. CNS Neurol Disord Drug Targets 17(9):696&#x2013;705</Citation><ArticleIdList><ArticleId IdType="pubmed">30113005</ArticleId><ArticleId IdType="doi">10.2174/1871527317666180816100203</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyango IG (2018) Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease. Neural Regen Res 13(1):19&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pubmed">29451200</ArticleId><ArticleId IdType="pmc">5840984</ArticleId><ArticleId IdType="doi">10.4103/1673-5374.224362</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8(6):595&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pubmed">27025652</ArticleId><ArticleId IdType="pmc">4888851</ArticleId><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong YC, Krainc D (2017) &#x3b1;-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23(2):1&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pubmed">28170377</ArticleId><ArticleId IdType="doi">10.1038/nm.4269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh R, Tabrizi SJ (2018) Clinical features of Huntington's disease. Adv Exp Med Biol 1049:1&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">29427096</ArticleId><ArticleId IdType="doi">10.1007/978-3-319-71779-1_1</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofani R, Crippa V, Rusmini P, Cicardi ME, Meroni M, Licata NV et al (2017) Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. Autophagy 13(8):1280&#x2013;1303</Citation><ArticleIdList><ArticleId IdType="pubmed">28402699</ArticleId><ArticleId IdType="pmc">5584856</ArticleId><ArticleId IdType="doi">10.1080/15548627.2017.1308985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariosa AR, Klionsky DJ (2016) Autophagy core machinery: overcoming spatial barriers in neurons. J Mol Med (Berl) 94(11):1217&#x2013;1227</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-016-1461-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K (2019) Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement (N Y) 5:272&#x2013;293</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.05.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RM, Hadjichrysanthou C, Evans S, Wong MM (2017) Why do so many clinical trials of therapies for Alzheimer&#x2019;s disease fail? Lancet 390(10110):2327&#x2013;2329</Citation><ArticleIdList><ArticleId IdType="pubmed">29185425</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(17)32399-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, Vandenberghe LH (2019) Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101(5):839&#x2013;862</Citation><ArticleIdList><ArticleId IdType="pubmed">30844402</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman BE, Ravina BM, Bankiewicz KS, Paul SM, Sah DWY (2018) Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov 17(9):641&#x2013;659</Citation><ArticleIdList><ArticleId IdType="pubmed">30093643</ArticleId><ArticleId IdType="doi">10.1038/nrd.2018.110</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghian T, Marosfoi MG, Puri AS, Cataltepe OI, King RM, Diffie EB et al (2020) A safe and reliable technique for CNS delivery of AAV vectors in the Cisterna Magna. Mol Ther 28(2):411&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pubmed">31813800</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2019.11.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Gao G (2014) State-of-the-art human gene therapy: Part II. Gene therapy strategies and clinical applications. Discov Med 18(98):151&#x2013;161</Citation><ArticleIdList><ArticleId IdType="pubmed">25227756</ArticleId><ArticleId IdType="pmc">4440458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotterman MA, Chalberg TW, Schaffer DV (2015) Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 17:63&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pubmed">26643018</ArticleId><ArticleId IdType="doi">10.1146/annurev-bioeng-071813-104938</ArticleId></ArticleIdList></Reference><Reference><Citation>Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12(5):341&#x2013;355</Citation><ArticleIdList><ArticleId IdType="pubmed">21499295</ArticleId><ArticleId IdType="doi">10.1038/nrg2988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M et al (2017) AAV5-Factor VIII gene transfer in severe Hemophilia A. N Engl J Med 377(26):2519&#x2013;2530</Citation><ArticleIdList><ArticleId IdType="pubmed">29224506</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1708483</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365(25):2357&#x2013;2365</Citation><ArticleIdList><ArticleId IdType="pubmed">22149959</ArticleId><ArticleId IdType="pmc">3265081</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1108046</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J et al (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371(21):1994&#x2013;2004</Citation><ArticleIdList><ArticleId IdType="pubmed">25409372</ArticleId><ArticleId IdType="pmc">4278802</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1407309</ArticleId></ArticleIdList></Reference><Reference><Citation>George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J et al (2017) Hemophilia B gene therapy with a high-specific-activity Factor IX variant. N Engl J Med 377(23):2215&#x2013;2227</Citation><ArticleIdList><ArticleId IdType="pubmed">29211678</ArticleId><ArticleId IdType="pmc">6029626</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1708538</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM et al (2008) Safety and efficacy of gene transfer for Leber&#x2019;s congenital amaurosis. N Engl J Med 358(21):2240&#x2013;2248</Citation><ArticleIdList><ArticleId IdType="pubmed">18441370</ArticleId><ArticleId IdType="pmc">2829748</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0802315</ArticleId></ArticleIdList></Reference><Reference><Citation>Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al (2008) Effect of gene therapy on visual function in Leber&#x2019;s congenital amaurosis. N Engl J Med 358(21):2231&#x2013;2239</Citation><ArticleIdList><ArticleId IdType="pubmed">18441371</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0802268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C et al (2015) Long-term effect of gene therapy on Leber&#x2019;s congenital amaurosis. N Engl J Med 372(20):1887&#x2013;1897</Citation><ArticleIdList><ArticleId IdType="pubmed">25938638</ArticleId><ArticleId IdType="pmc">4497809</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1414221</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713&#x2013;1722</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakrishnan B, Jayandharan GR (2014) Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther 14(2):86&#x2013;100</Citation><ArticleIdList><ArticleId IdType="pubmed">24588706</ArticleId><ArticleId IdType="doi">10.2174/1566523214666140302193709</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonntag F, Schmidt K, Kleinschmidt JA (2010) A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 107(22):10220&#x2013;10225</Citation><ArticleIdList><ArticleId IdType="pubmed">20479244</ArticleId><ArticleId IdType="pmc">2890453</ArticleId><ArticleId IdType="doi">10.1073/pnas.1001673107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V et al (2010) High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 17(4):503&#x2013;510</Citation><ArticleIdList><ArticleId IdType="pubmed">19956269</ArticleId><ArticleId IdType="doi">10.1038/gt.2009.157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JF (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15(11):840&#x2013;848</Citation><ArticleIdList><ArticleId IdType="pubmed">18418418</ArticleId><ArticleId IdType="doi">10.1038/gt.2008.65</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuso E, Mingozzi F, Bosch F (2010) Production, purification and characterization of adeno-associated vectors. Curr Gene Ther 10(6):423&#x2013;436</Citation><ArticleIdList><ArticleId IdType="pubmed">21054248</ArticleId><ArticleId IdType="doi">10.2174/156652310793797685</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong B, Nakai H, Xiao W (2010) Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 18(1):87&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pubmed">19904236</ArticleId><ArticleId IdType="doi">10.1038/mt.2009.258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Yang H, Colosi P (2010) Effect of genome size on AAV vector packaging. Mol Ther 18(1):80&#x2013;86</Citation><ArticleIdList><ArticleId IdType="pubmed">19904234</ArticleId><ArticleId IdType="doi">10.1038/mt.2009.255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Duan D (2007) Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev 24:165&#x2013;177</Citation><ArticleIdList><ArticleId IdType="pubmed">18059632</ArticleId><ArticleId IdType="doi">10.1080/02648725.2007.10648098</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapani I, Colella P, Sommella A, Iodice C, Cesi G, de Simone S et al (2014) Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 6(2):194&#x2013;211</Citation><ArticleIdList><ArticleId IdType="pubmed">24150896</ArticleId><ArticleId IdType="doi">10.1002/emmm.201302948</ArticleId></ArticleIdList></Reference><Reference><Citation>Colella P, Trapani I, Cesi G, Sommella A, Manfredi A, Puppo A et al (2014) Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther 21(4):450&#x2013;456</Citation><ArticleIdList><ArticleId IdType="pubmed">24572793</ArticleId><ArticleId IdType="doi">10.1038/gt.2014.8</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapani I, Toriello E, de Simone S, Colella P, Iodice C, Polishchuk EV et al (2015) Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum Mol Genet 24(23):6811&#x2013;6825</Citation><ArticleIdList><ArticleId IdType="pubmed">26420842</ArticleId><ArticleId IdType="pmc">4634381</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddv386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lostal W, Bartoli M, Bourg N, Roudaut C, Bentaib A, Miyake K et al (2010) Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 19(10):1897&#x2013;1907</Citation><ArticleIdList><ArticleId IdType="pubmed">20154340</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddq065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondergaard PC, Griffin DA, Pozsgai ER, Johnson RW, Grose WE, Heller KN et al (2015) AAV. Dysferlin overlap vectors restore function in dysferlinopathy animal models. Ann Clin Transl Neurol 2(3):256&#x2013;270</Citation><ArticleIdList><ArticleId IdType="pubmed">25815352</ArticleId><ArticleId IdType="pmc">4369275</ArticleId><ArticleId IdType="doi">10.1002/acn3.172</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter RA, Griffin DA, Sondergaard PC, Johnson RW, Pozsgai ER, Heller KN et al (2018) Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Hum Gene Ther 29(7):749&#x2013;762</Citation><ArticleIdList><ArticleId IdType="pubmed">28707952</ArticleId><ArticleId IdType="pmc">6066196</ArticleId><ArticleId IdType="doi">10.1089/hum.2017.062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodippili K, Hakim CH, Pan X, Yang HT, Yue Y, Zhang Y et al (2018) Dual AAV gene therapy for duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model. Hum Gene Ther 29(3):299&#x2013;311</Citation><ArticleIdList><ArticleId IdType="pubmed">28793798</ArticleId><ArticleId IdType="pmc">5865264</ArticleId><ArticleId IdType="doi">10.1089/hum.2017.095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao G, Vandenberghe LH, Wilson JM (2005) New recombinant serotypes of AAV vectors. Curr Gene Ther 5(3):285&#x2013;297</Citation><ArticleIdList><ArticleId IdType="pubmed">15975006</ArticleId><ArticleId IdType="doi">10.2174/1566523054065057</ArticleId></ArticleIdList></Reference><Reference><Citation>Asokan A, Schaffer DV, Samulski RJ (2012) The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20(4):699&#x2013;708</Citation><ArticleIdList><ArticleId IdType="pubmed">22273577</ArticleId><ArticleId IdType="pmc">3321598</ArticleId><ArticleId IdType="doi">10.1038/mt.2011.287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y et al (2016) An essential receptor for adeno-associated virus infection. Nature 530(7588):108&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">26814968</ArticleId><ArticleId IdType="pmc">4962915</ArticleId><ArticleId IdType="doi">10.1038/nature16465</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek AM, Zabaleta N, Zinn E, Pillay S, Zengel J, Porter C et al (2020) GPR108 is a highly conserved AAV entry factor. Mol Ther 28(2):367&#x2013;381</Citation><ArticleIdList><ArticleId IdType="pubmed">31784416</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2019.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Colella P, Ronzitti G, Mingozzi F (2018) Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev 8:87&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pubmed">29326962</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2017.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE et al (2007) CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13(4):419&#x2013;422</Citation><ArticleIdList><ArticleId IdType="pubmed">17369837</ArticleId><ArticleId IdType="doi">10.1038/nm1549</ArticleId></ArticleIdList></Reference><Reference><Citation>Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G et al (2018) Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun 9(1):4098. https://doi.org/10.1038/s41467-018-06621-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06621-3</ArticleId><ArticleId IdType="pubmed">30291246</ArticleId><ArticleId IdType="pmc">6173722</ArticleId></ArticleIdList></Reference><Reference><Citation>Salas D, Kwikkers KL, Zabaleta N, Bazo A, Petry H, van Deventer SJ et al (2019) Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. Blood Adv 3(17):2632&#x2013;2641</Citation><ArticleIdList><ArticleId IdType="pubmed">31501158</ArticleId><ArticleId IdType="pmc">6737410</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2019000380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin B, Veron P, Leborgne C, Deschamps JY, Moullec S, Fromes Y et al (2020) Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. Sci Rep 10(1):864. https://doi.org/10.1038/s41598-020-57893-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-57893-z</ArticleId><ArticleId IdType="pubmed">31965041</ArticleId><ArticleId IdType="pmc">6972890</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdera HC, Kuranda K, Mingozzi F (2020) AAV Vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 28(3):723&#x2013;746</Citation><ArticleIdList><ArticleId IdType="pubmed">31972133</ArticleId><ArticleId IdType="pmc">7054726</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2019.12.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, Maguire AM et al (2001) Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10(26):3075&#x2013;3081</Citation><ArticleIdList><ArticleId IdType="pubmed">11751689</ArticleId><ArticleId IdType="doi">10.1093/hmg/10.26.3075</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm D, Buning H (2017) Small but increasingly mighty: latest advances in AAV vector research, design, and evolution. Hum Gene Ther 28(11):1075&#x2013;1086</Citation><ArticleIdList><ArticleId IdType="pubmed">28835125</ArticleId><ArticleId IdType="doi">10.1089/hum.2017.172</ArticleId></ArticleIdList></Reference><Reference><Citation>Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12(3):342&#x2013;347</Citation><ArticleIdList><ArticleId IdType="pubmed">16474400</ArticleId><ArticleId IdType="doi">10.1038/nm1358</ArticleId></ArticleIdList></Reference><Reference><Citation>Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA et al (2009) AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114(10):2077&#x2013;2086</Citation><ArticleIdList><ArticleId IdType="pubmed">19506302</ArticleId><ArticleId IdType="pmc">2744569</ArticleId><ArticleId IdType="doi">10.1182/blood-2008-07-167510</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YH, Chang M, Davidson BL (2009) Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15(10):1215&#x2013;1218</Citation><ArticleIdList><ArticleId IdType="pubmed">19749771</ArticleId><ArticleId IdType="pmc">3181494</ArticleId><ArticleId IdType="doi">10.1038/nm.2025</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10(2):302&#x2013;317</Citation><ArticleIdList><ArticleId IdType="pubmed">15294177</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2004.05.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L et al (2007) Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18(3):195&#x2013;206</Citation><ArticleIdList><ArticleId IdType="pubmed">17343566</ArticleId><ArticleId IdType="doi">10.1089/hum.2006.178</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschauer DF, Kreuz S, Rumpel S (2013) Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One 8(9):e76310. https://doi.org/10.1371/journal.pone.0076310</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076310</ArticleId><ArticleId IdType="pubmed">24086725</ArticleId><ArticleId IdType="pmc">3785459</ArticleId></ArticleIdList></Reference><Reference><Citation>Vite CH, Passini MA, Haskins ME, Wolfe JH (2003) Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther 10(22):1874&#x2013;1881</Citation><ArticleIdList><ArticleId IdType="pubmed">14502216</ArticleId><ArticleId IdType="doi">10.1038/sj.gt.3302087</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain GP, Prociuk M, Bagel JH, O'Donnell P, Berger K, Drobatz K et al (2014) Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain. Gene Ther 21(1):28&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pubmed">24131981</ArticleId><ArticleId IdType="doi">10.1038/gt.2013.54</ArticleId></ArticleIdList></Reference><Reference><Citation>Watakabe A, Ohtsuka M, Kinoshita M, Takaji M, Isa K, Mizukami H et al (2015) Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res 93:144&#x2013;157</Citation><ArticleIdList><ArticleId IdType="pubmed">25240284</ArticleId><ArticleId IdType="doi">10.1016/j.neures.2014.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27(1):59&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pubmed">19098898</ArticleId><ArticleId IdType="doi">10.1038/nbt.1515</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ et al (2014) Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett 576:73&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pubmed">24882721</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2014.05.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19(6):1058&#x2013;1069</Citation><ArticleIdList><ArticleId IdType="pubmed">21487395</ArticleId><ArticleId IdType="pmc">3129805</ArticleId><ArticleId IdType="doi">10.1038/mt.2011.72</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21(6):704&#x2013;712</Citation><ArticleIdList><ArticleId IdType="pubmed">20095819</ArticleId><ArticleId IdType="doi">10.1089/hum.2009.182</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidoo J, Stanek LM, Ohno K, Trewman S, Samaranch L, Hadaczek P et al (2018) extensive transduction and enhanced spread of a modified AAV2 Capsid in the non-human primate CNS. Mol Ther 26(10):2418&#x2013;2430</Citation><ArticleIdList><ArticleId IdType="pubmed">30057240</ArticleId><ArticleId IdType="pmc">6171051</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2018.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury SR, Harris AF, Cabral DJ, Keeler AM, Sapp E, Ferreira JS et al (2016) Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. Mol Ther 24(4):726&#x2013;735</Citation><ArticleIdList><ArticleId IdType="pubmed">26708003</ArticleId><ArticleId IdType="pmc">4886933</ArticleId><ArticleId IdType="doi">10.1038/mt.2015.231</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury SR, Fitzpatrick Z, Harris AF, Maitland SA, Ferreira JS, Zhang Y et al (2016) In vivo selection yields AAV-B1 Capsid for central nervous system and muscle gene therapy. Mol Ther 24(7):1247&#x2013;1257</Citation><ArticleIdList><ArticleId IdType="pubmed">27117222</ArticleId><ArticleId IdType="pmc">5088762</ArticleId><ArticleId IdType="doi">10.1038/mt.2016.84</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanlon KS, Meltzer JC, Buzhdygan T, Cheng MJ, Sena-Esteves M, Bennett RE et al (2019) Selection of an efficient AAV vector for robust CNS transgene expression. Mol Ther Methods Clin Dev 15:320&#x2013;332</Citation><ArticleIdList><ArticleId IdType="pubmed">31788496</ArticleId><ArticleId IdType="pmc">6881693</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2019.10.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A et al (2016) Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 34(2):204&#x2013;209</Citation><ArticleIdList><ArticleId IdType="pubmed">26829320</ArticleId><ArticleId IdType="pmc">5088052</ArticleId><ArticleId IdType="doi">10.1038/nbt.3440</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki Y, Konno A, Mochizuki R, Shinohara Y, Nitta K, Okada Y et al (2018) Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci Lett 665:182&#x2013;188</Citation><ArticleIdList><ArticleId IdType="pubmed">29175632</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2017.11.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM (2018) The neurotropic properties of AAV-PHP.B are limited to C57BL/6J Mice. Mol Ther 26(3):664&#x2013;668</Citation><ArticleIdList><ArticleId IdType="pubmed">29428298</ArticleId><ArticleId IdType="pmc">5911151</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2018.01.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguore WA, Domire JS, Button D, Wang Y, Dufour BD, Srinivasan S et al (2019) AAV-PHP.B Administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice. Mol Ther 27(11):2018&#x2013;2037</Citation><ArticleIdList><ArticleId IdType="pubmed">31420242</ArticleId><ArticleId IdType="pmc">6838922</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2019.07.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito G, Giannelli SG, Ordazzo G, Bido S, Castoldi V, Indrigo M et al (2017) AAV-PHP.B-Mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Mol Ther 25(12):2727&#x2013;2742</Citation><ArticleIdList><ArticleId IdType="pubmed">28882452</ArticleId><ArticleId IdType="pmc">5768559</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2017.08.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer&#x2019;s disease. Lancet 377(9770):1019&#x2013;1031</Citation><ArticleIdList><ArticleId IdType="pubmed">21371747</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(10)61349-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16(6):358&#x2013;372</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId><ArticleId IdType="doi">10.1038/nrn3880</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves S, Churlaud G, Audrain M, Michaelsen-Preusse K, Fol R, Souchet B et al (2017) Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer&#x2019;s disease mice. Brain 140(3):826&#x2013;842</Citation><ArticleIdList><ArticleId IdType="pubmed">28003243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, Zhang G, Morrison CM, Bosch ME, Weir RA, Lu Y et al (2015) AAV2/1 CD74 Gene transfer reduces beta-amyloidosis and improves learning and memory in a mouse model of Alzheime&#x2019;s disease. Mol Ther 23(11):1712&#x2013;1721</Citation><ArticleIdList><ArticleId IdType="pubmed">26227349</ArticleId><ArticleId IdType="pmc">4817947</ArticleId><ArticleId IdType="doi">10.1038/mt.2015.142</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Team ANS et al (2018) Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol 75(7):834&#x2013;841</Citation><ArticleIdList><ArticleId IdType="pubmed">29582053</ArticleId><ArticleId IdType="pmc">5885277</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.0233</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle MJ, Baltanas FC, Kovacs I, Nagahara AH, Barba D, Tuszynski MH (2020) Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer&#x2019;s disease identifies a need for improved vector delivery. Hum Gene Ther 31(7&#x2013;8):415&#x2013;422</Citation><ArticleIdList><ArticleId IdType="pubmed">32126838</ArticleId><ArticleId IdType="doi">10.1089/hum.2019.367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Gottesdiener AJ, Parmar M, Li M, Kaminsky SM, Chiuchiolo MJ et al (2016) Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer&#x2019;s disease mouse models. Neurobiol Aging 44:159&#x2013;117</Citation><ArticleIdList><ArticleId IdType="pubmed">27318144</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.04.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg JB, Kaplitt MG, De BP, Chen A, Flagiello T, Salami C et al (2018) AAVrh.10-Mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer&#x2019;s disease. Hum Gene Ther Clin Dev 29(1):24&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">29409358</ArticleId><ArticleId IdType="pmc">5870071</ArticleId><ArticleId IdType="doi">10.1089/humc.2017.231</ArticleId></ArticleIdList></Reference><Reference><Citation>Athauda D, Foltynie T (2018) Drug repurposing in Parkinson&#x2019;s disease. CNS Drugs 32(8):747&#x2013;761</Citation><ArticleIdList><ArticleId IdType="pubmed">30066310</ArticleId><ArticleId IdType="doi">10.1007/s40263-018-0548-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignataro D, Sucunza D, Rico AJ, Dopeso-Reyes IG, Roda E, Rodriguez-Perez AI et al (2018) Gene therapy approaches in the non-human primate model of Parkinson&#x2019;s disease. J Neural Transm (Vienna) 125(3):575&#x2013;589</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1681-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH (2019) Human gene therapy approaches for the treatment of Parkinson&#x2019;s disease: an overview of current and completed clinical trials. Parkinsonism Relat Disord 66:16&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">31324556</ArticleId><ArticleId IdType="doi">10.1016/j.parkreldis.2019.07.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P et al (2012) Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson&#x2019;s disease. Hum Gene Ther 23(4):377&#x2013;381</Citation><ArticleIdList><ArticleId IdType="pubmed">22424171</ArticleId><ArticleId IdType="pmc">4530392</ArticleId><ArticleId IdType="doi">10.1089/hum.2011.220</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS et al (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70(21):1980&#x2013;1983</Citation><ArticleIdList><ArticleId IdType="pubmed">18401019</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000312381.29287.ff</ArticleId></ArticleIdList></Reference><Reference><Citation>Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP et al (2019) Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson&#x2019;s disease. Ann Neurol 85(5):704&#x2013;714</Citation><ArticleIdList><ArticleId IdType="pubmed">30802998</ArticleId><ArticleId IdType="pmc">6593762</ArticleId><ArticleId IdType="doi">10.1002/ana.25450</ArticleId></ArticleIdList></Reference><Reference><Citation>Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC et al (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383(9923):1138&#x2013;1146</Citation><ArticleIdList><ArticleId IdType="pubmed">24412048</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(13)61939-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart HJ, Ralph GS, Fong-Wong L, Strickland I, McCloskey L, Barnes L et al (2016) Optimizing transgene configuration and protein fusions to maximize dopamine production for the gene therapy of Parkinson&#x2019;s disease. Hum Gene Ther Clin Dev 27(3):100&#x2013;110</Citation><ArticleIdList><ArticleId IdType="pubmed">27470285</ArticleId><ArticleId IdType="doi">10.1089/humc.2016.056</ArticleId></ArticleIdList></Reference><Reference><Citation>Badin RA, Binley K, Van Camp N, Jan C, Gourlay J, Robert C et al (2019) Gene therapy for Parkinson&#x2019;s disease: preclinical evaluation of optimally configured TH:CH1 fusion for maximal dopamine synthesis. Mol Ther Methods Clin Dev 14:206&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">31406701</ArticleId><ArticleId IdType="pmc">6685641</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2019.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459&#x2013;466</Citation><ArticleIdList><ArticleId IdType="pubmed">16429411</ArticleId><ArticleId IdType="doi">10.1002/ana.20737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr et al (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60(1):69&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pubmed">12525720</ArticleId><ArticleId IdType="doi">10.1212/WNL.60.1.69</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA et al (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson&#x2019;s disease: an open-label, phase I trial. Lancet Neurol 7(5):400&#x2013;408</Citation><ArticleIdList><ArticleId IdType="pubmed">18387850</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(08)70065-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N et al (2010) Gene delivery of AAV2-neurturin for Parkinson&#x2019;s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9(12):1164&#x2013;1172</Citation><ArticleIdList><ArticleId IdType="pubmed">20970382</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70254-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M et al (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78(2):248&#x2013;257</Citation><ArticleIdList><ArticleId IdType="pubmed">26061140</ArticleId><ArticleId IdType="doi">10.1002/ana.24436</ArticleId></ArticleIdList></Reference><Reference><Citation>LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN et al (2011) AAV2-GAD gene therapy for advanced Parkinson&#x2019;s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10(4):309&#x2013;319</Citation><ArticleIdList><ArticleId IdType="pubmed">21419704</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(11)70039-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG et al (2017) Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson&#x2019;s disease. JCI Insight 2(7):e90133. https://doi.org/10.1172/jci.insight.90133</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.90133</ArticleId><ArticleId IdType="pubmed">28405611</ArticleId><ArticleId IdType="pmc">5374069</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsen TM, Woldbye DPD (2018) Gene therapy for Parkinson&#x2019;s disease, an update. J Parkinsons Dis 8(2):195&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pubmed">29710735</ArticleId><ArticleId IdType="pmc">6027861</ArticleId><ArticleId IdType="doi">10.3233/JPD-181331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942&#x2013;955</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM (2015) Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol Clin 33(4):735&#x2013;748</Citation><ArticleIdList><ArticleId IdType="pubmed">26515618</ArticleId><ArticleId IdType="pmc">4629510</ArticleId><ArticleId IdType="doi">10.1016/j.ncl.2015.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H et al (2013) Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 21(12):2148&#x2013;2159</Citation><ArticleIdList><ArticleId IdType="pubmed">24008656</ArticleId><ArticleId IdType="pmc">3863799</ArticleId><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR et al (2018) Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS. Mol Ther Nucleic Acids 12:75&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pubmed">30195799</ArticleId><ArticleId IdType="pmc">6023790</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2018.04.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q et al (2014) Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet 23(3):668&#x2013;681</Citation><ArticleIdList><ArticleId IdType="pubmed">24108104</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddt454</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Cardozo B, Metterville JP, Toro Cabrera GC, Song L et al (2016) Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1(G93A) mice and nonhuman primates. Hum Gene Ther 27(1):19&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">26710998</ArticleId><ArticleId IdType="doi">10.1089/hum.2015.122</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Todeasa SH, Cabrera GT, Salameh JS, ElMallah MK, Mueller C et al (2016) Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol 79(4):687&#x2013;700</Citation><ArticleIdList><ArticleId IdType="pubmed">26891182</ArticleId><ArticleId IdType="pmc">5374859</ArticleId><ArticleId IdType="doi">10.1002/ana.24618</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH Jr et al (2018) Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med 10(465):eaau6414. https://doi.org/10.1126/scitranslmed.aau6414</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6414</ArticleId><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Biferi MG, Cohen-Tannoudji M, Cappelletto A, Giroux B, Roda M, Astord S et al (2017) A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model. Mol Ther 25(9):2038&#x2013;2052</Citation><ArticleIdList><ArticleId IdType="pubmed">28663100</ArticleId><ArticleId IdType="pmc">5589057</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2017.05.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M et al (2019) Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol Ther Nucleic Acids 16:26&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">30825670</ArticleId><ArticleId IdType="pmc">6393708</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I et al (2019) Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients. Mol Ther Nucleic Acids 14:593&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pubmed">30776581</ArticleId><ArticleId IdType="pmc">6378669</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2019.01.010</ArticleId></ArticleIdList></Reference><Reference><Citation>McEachin ZT, Donsante A, Boulis N (2016) Gene therapy for the treatment of neurological disorders: amyotrophic lateral sclerosis. Methods Mol Biol 1382:399&#x2013;408</Citation><ArticleIdList><ArticleId IdType="pubmed">26611602</ArticleId><ArticleId IdType="doi">10.1007/978-1-4939-3271-9_28</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Sena-Esteves M (2016) Adeno associated viral vector delivered RNAi for gene therapy of SOD1 amyotrophic lateral sclerosis. Front Mol Neurosci 9:56. https://doi.org/10.3389/fnmol.2016.00056</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2016.00056</ArticleId><ArticleId IdType="pubmed">27531973</ArticleId><ArticleId IdType="pmc">4969298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M, Ciotti C, Cohen-Tannoudji M, Biferi MG (2019) Gene therapy for ALS-A perspective. Int J Mol Sci 20(18):4388. https://doi.org/10.3390/ijms20184388</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184388</ArticleId><ArticleId IdType="pmc">6771059</ArticleId><ArticleId IdType="pubmed">6771059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>